Healthcare

BlinkLab (ASX:BB1) has announced positive findings from its European case-control study evaluating smartphone-based digital neurobehavioural biomarkers for attention-deficit/hyperactivity disorder (ADHD) assessment. The study represents a key development milestone as the company expands its artificial intelligence-driven diagnostic platform beyond autism and explores applications in a …

Memphasys (ASX:MEM) has announced the expansion of its European commercial strategy through an exclusive commercialisation agreement for its Felix™ System in Poland. The agreement with Warsaw-based TK Biotech represents another step in the company’s international roll-out following regulatory approval in Europe.

AdAlta Limited (ASX:1AD) has announced a significant clinical milestone from its ongoing investigator-initiated trial of EW-001, its lead CAR-T cell therapy candidate being evaluated in patients with advanced mesothelioma.

● AstraZeneca (NYSE:AZN) shares fell about 7% in London after the Financial Times and Reuters reported preliminary merger talks with Bristol Myers Squibb.

Summerset Group Holdings Ltd (ASX:SNZ) was trading at $6.99 during the session, with a daily change of -0.14%. The market context is summarised in the table below.

Australian equities finished higher across major benchmarks during the session. The S&P/ASX 200 Health Care Index (XHJ) advanced 635.20 points or 2.36% to reach 27,540.10. The S&P/ASX 200 rose 1.40% to 9,145.80 and the All Ordinaries closed at 9,311.90, up 1.45%.

Telix Pharmaceuticals Ltd (ASX:TLX) closed on 4 August 2026 at $14.41, gaining 0.91% or $0.13 during the trading session. The movement came during a positive session for Australian equities, with the S&P/ASX 200 (ASX:XJO) closing at 9,145.80, up 1.40% on 4 August 2026.